A single dose of the Pfizer Covid-19 vaccine may boost protection against Covid-19 variants for those who have previously had the virus, according to a new study supported by the BRC.
A research paper from a team led by UCLH consultant haematologist Prof Marie Scully which looks at rare cases of blood clots in the brain and low platelets seen in some patients after vaccination has been published in the prestigious New England Journal of Medicine.
Achilles Therapeutics, a company built on research at UCLH, UCL Cancer Institute and the Francis Crick Institute has successfully raised $175.5 million through its initial public offering in the United States.
UCL scientists have used artificial intelligence to identify three new multiple sclerosis subtypes. Researchers say this will help identify people more likely to have disease progression and help target treatments.
A single dose of either the Oxford-AstraZeneca or Pfizer vaccine gives residents of care homes substantial protection against SARS-CoV-2 infection after four weeks, according to a study led by UCL researchers.
The majority of survivors who left hospital following Covid-19 did not fully recover five months after discharge and continued to experience negative impacts on their physical and mental health, according to results from the PHOSP-COVID study.
UCLH consultant supported by the BRC Professor Sir Alimuddin (Ali) Zumla guest edits a special edition of the International Journal of Infectious Diseases (IJID) dedicated to Tuberculosis to mark World TB Day.
People with heart failure and atrial fibrillation who are hospitalised with Covid-19 are at greater risk of death, according to a large European study involving UCLH.
UCLH and Microsoft have announced a new strategic research and innovation collaboration to develop and apply advances in artificial intelligence (AI) and digital technologies for the future of healthcare delivery in the NHS.
A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai is set to begin in the UK and US.
The UCLH and UCL team behind a life-saving breathing device for Covid-19 patients have won the 2020 Health Service Journal (HSJ) Award for Acute Innovation of the Year.